Phase 1/2 Study of Alemtuzumab with Dose-Adjusted EPOCH in Untreated Aggressive T and NK cell Lymphomas

Podobne zapisy

• Phase II trial of dose-adjusted EPOCH in untreated systemic anaplastic large cell lymphoma
  od: Dunleavy, Kieron, i wsp.
  Wydane: (2016)
• Phase I dose escalation study of the anti-CD2 monoclonal antibody, siplizumab, with DA-EPOCH-R in aggressive peripheral T-cell lymphomas
  od: Roswarski, Joseph, i wsp.
  Wydane: (2017)
• A Prospective Multicenter Phase 2 Study of Dose-Adjusted-EPOCH-R in Untreated MYC-Rearranged Aggressive B-cell Lymphoma
  od: Dunleavy, Kieron, i wsp.
  Wydane: (2018)
• MYC gene rearrangement in diffuse large B-cell lymphoma does not confer a worse prognosis following dose-adjusted EPOCH-R
  od: Lai, Catherine, i wsp.
  Wydane: (2017)
• Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma
  od: Roschewski, Mark, i wsp.
  Wydane: (2020)